CG
JUNO

Cutler Group’s Juno Therapeutics, Inc. JUNO Stock Holding History

Cutler Group’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-31,800
Closed -$351K – 5811
2017
Q4 		$351K Sell
31,800
-10,800
-25% -$539K 0.01% 687
2017
Q3 		$443K Sell
42,600
-24,000
-36% -$818K 0.02% 717
2017
Q2 		$367K Buy
66,600
+10,100
+18% +$249K 0.01% 873
2017
Q1 		$97K Sell
56,500
-53,000
-48% -$1.14M ﹤0.01% 1771
2016
Q4 		$54K Sell
109,500
-1,200
-1% -$29.4K ﹤0.01% 2474
2016
Q3 		$93K Buy
110,700
+47,100
+74% +$1.47M ﹤0.01% 1886
2016
Q2 		$244K Buy
63,600
+27,700
+77% +$1.15M 0.01% 978
2016
Q1 		$120K Buy
35,900
+1,400
+4% +$48.8K 0.01% 1448
2015
Q4 		$112K Buy
+34,500
New +$1.71M 0.01% 1659

Other funds holding JUNO

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Cutler Group's JUNO Position: Q1 2018 in Review

Cutler Group sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 16,700 shares — an estimated $763K sold.

Cutler Group first reported a position in JUNO in Q4 2015 and held it in 9 quarters. The position peaked at $890K in Q2 2016. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

  • Cutler Group reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Cutler Group sold 16,700 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $763K.
  • Cutler Group first reported a position in Juno Therapeutics, Inc. in Q4 2015 and held it in 9 quarters.
  • Cutler Group's Juno Therapeutics, Inc. position peaked at $890K in Q2 2016.
  • 2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on Cutler Group's 13F filing for Q1 2018, filed 11 May 2018.